Benchmark upgraded Nephros to Speculative Buy from Hold with a $5 price target after the company reported “solid” results for Q4 and 2023 as a whole. The firm, which forecasts that Nephros will post revenues of $17.1M, up 20% year-over-year in FY24, sees a “positive outlook and quarterly comparisons going forward.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NEPH: